Literature DB >> 7770604

The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

K K Gnanalingham1, A J Hunter, P Jenner, C D Marsden.   

Abstract

The effects of co-administration of quinpirole with benzazepine D1 dopamine (DA) agonists possessing full/supramaximal (SKF 80723 and SKF 82958), partial (SKF 38393 and SKF 75670) and no efficacies (SKF 83959) in stimulating adenylate cyclase (AC) were investigated in rodent and primate models of Parkinson's disease (PD). In rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, co-administration of SKF 38393 (7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine), SKF 75670 (3-CH3 analogue), SKF 80723 (6-Br analogue), SKF 83959 (6-Cl, 3-CH3, 3'-CH3 analogue) and SKF 82958 (6-Cl, 3-C3H5 analogue) strongly potentiated the contralateral circling induced by quinpirole. In MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treated common marmosets, administration of quinpirole alone increased locomotor activity and reversed motor deficits. Grooming and oral activity were unaltered. Co-administration of SKF 38393 and SKF 75670 inhibited the quinpirole-induced changes in locomotor activity and motor disability. The combined treatment of SKF 80723 or SKF 82958 with quinpirole had no overall effect on locomotor activity or motor disability. In contrast, SKF 83959 extended the duration of the quinpirole-induced increase in locomotor activity with corresponding decreases in motor disability. Co-administration of high doses of SKF 82958 and more especially SKF 83959 and SKF 80723, with quinpirole induced hyperexcitability and seizures. Oral activity and grooming were unaltered following the co-administration of benzazepine derivatives with quinpirole. The ability of some benzazepine D1 DA agonists to prolong the antiparkinsonian effects of quinpirole in the MPTP-treated marmoset may indicate a role for certain D1 DA agonists in the clinical treatment of PD. In general, the behavioural responses to the combined administration of benzazepines with quinpirole in the 6-OHDA lesioned rat and more especially the MPTP-treated marmoset failed to correlate with their ability to stimulate AC. These observations further implicate a behavioural role for D1 DA receptors not linked to AC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770604     DOI: 10.1007/bf02246103

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates.

Authors:  N M Rupniak; S Boyce; M Steventon; S D Iversen
Journal:  Clin Neuropharmacol       Date:  1992-08       Impact factor: 1.592

2.  D-1 dopamine receptors and the topography of unconditioned motor behaviour: studies with the selective, 'full efficacy' benzazepine D-1 agonist SKF 83189.

Authors:  S A Daly; J L Waddington
Journal:  J Psychopharmacol       Date:  1992-01       Impact factor: 4.153

3.  The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.

Authors:  M Nomoto; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1988-11-11       Impact factor: 3.046

4.  Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.

Authors:  M Mashurano; J L Waddington
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

5.  Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase.

Authors:  R P Downes; J L Waddington
Journal:  Eur J Pharmacol       Date:  1993-03-30       Impact factor: 4.432

6.  Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.

Authors:  C Rouillard; P J Bédard; T Di Paolo
Journal:  Eur J Pharmacol       Date:  1990-08-28       Impact factor: 4.432

7.  The chemical basis for the blockade of the D-1 dopamine receptor by SCH 23390.

Authors:  Y Itoh; M Beaulieu; J W Kebabian
Journal:  Eur J Pharmacol       Date:  1984-04-13       Impact factor: 4.432

8.  Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.

Authors:  E F Domino; J Sheng
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

9.  Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.

Authors:  S P Close; A S Marriott; S Pay
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

10.  Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells.

Authors:  D F Schoors; G P Vauquelin; H De Vos; G Smets; B Velkeniers; L Vanhaelst; A G Dupont
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

View more
  12 in total

1.  Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.

Authors:  David Wirtshafter
Journal:  Pharmacol Biochem Behav       Date:  2007-01-20       Impact factor: 3.533

2.  Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.

Authors:  Rajeev I Desai; John L Neumeyer; Carol A Paronis; Phong Nguyen; Jack Bergman
Journal:  Eur J Pharmacol       Date:  2006-12-01       Impact factor: 4.432

Review 3.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

4.  Electrophysiological effects of SKF83959 on hippocampal CA1 pyramidal neurons: potential mechanisms for the drug's neuroprotective effects.

Authors:  Hong-Yuan Chu; Qinhua Gu; Guo-Zhang Jin; Guo-Yuan Hu; Xuechu Zhen
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

Review 5.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

6.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  Activation of phosphatidylinositol-linked novel D1 dopamine receptor contributes to the calcium mobilization in cultured rat prefrontal cortical astrocytes.

Authors:  Jue Liu; Fang Wang; Chao Huang; Li-Hong Long; Wen-Ning Wu; Fei Cai; Jiang-Hua Wang; Li-Qun Ma; Jian-Guo Chen
Journal:  Cell Mol Neurobiol       Date:  2008-10-31       Impact factor: 5.046

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.

Authors:  Lyndsey E Collins-Praino; Nicholas E Paul; Kristen L Rychalsky; James R Hinman; James J Chrobak; Patrick B Senatus; John D Salamone
Journal:  Front Syst Neurosci       Date:  2011-07-04

10.  Dopamine D1-D2 receptor heteromer in dual phenotype GABA/glutamate-coexpressing striatal medium spiny neurons: regulation of BDNF, GAD67 and VGLUT1/2.

Authors:  Melissa L Perreault; Theresa Fan; Mohammed Alijaniaram; Brian F O'Dowd; Susan R George
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.